New injection could tame high triglycerides

NCT ID NCT07100418

Ongoing Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental injection called HRS-7249 in 224 adults with hyperlipidemia (high fat levels in the blood). The goal is to see if it safely lowers triglycerides, a type of blood fat linked to heart disease. Participants receive either the drug or a placebo, and researchers track changes in triglyceride levels and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-7249 injection
What this could lead to: If successful, this could lead to a new treatment option for lowering high triglycerides in people with hyperlipidemia, potentially reducing heart disease risk.
What could go wrong: This is an early Phase 2 trial with only 224 participants, so results may not confirm effectiveness or safety. The drug may fail to show benefit or cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERLIPIDEMIA

Contacts and locations

Show contact details

Locations

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.